3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Specimen Handling
34
Carboplatin
32
pembrolizumab
28
Pemetrexed
27
Magnetic Resonance Spectroscopy
27
Cisplatin
22
Paclitaxel
15
Gemcitabine
13
durvalumab
12
Docetaxel
12
osimertinib
11
Nivolumab
11
atezolizumab
8
Immunoglobulin G
8
Disulfides
8
Taxes
7
Etoposide
7
130-nm albumin-bound paclitaxel
7
Radiotherapy
6
Radiosurgery
6
Radiation
6
Platinum
6
Cetuximab
6
Biopsy
6
X-Rays
5
1,2-diaminocyclohexaneplatinum II citrate
5
Ramucirumab
4
Observation
4
Irinotecan
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled